Literature DB >> 34903606

HDAC2 Facilitates Pancreatic Cancer Metastasis.

Lukas Krauß1, Bettina C Urban1, Sieglinde Hastreiter1, Carolin Schneider1, Patrick Wenzel1, Zonera Hassan1, Matthias Wirth2, Katharina Lankes1, Andrea Terrasi3, Christine Klement3,4, Filippo M Cernilogar3, Rupert Öllinger4, Niklas de Andrade Krätzig4, Thomas Engleitner4, Roland M Schmid1, Katja Steiger5,6, Roland Rad4,6, Oliver H Krämer7, Maximilian Reichert1,6, Gunnar Schotta3,8, Dieter Saur6,9, Günter Schneider1,6,10.   

Abstract

The mortality of patients with pancreatic ductal adenocarcinoma (PDAC) is strongly associated with metastasis, a multistep process that is incompletely understood in this disease. Although genetic drivers of PDAC metastasis have not been defined, transcriptional and epigenetic rewiring can contribute to the metastatic process. The epigenetic eraser histone deacetylase 2 (HDAC2) has been connected to less differentiated PDAC, but the function of HDAC2 in PDAC has not been comprehensively evaluated. Using genetically defined models, we show that HDAC2 is a cellular fitness factor that controls cell cycle in vitro and metastasis in vivo, particularly in undifferentiated, mesenchymal PDAC cells. Unbiased expression profiling detected a core set of HDAC2-regulated genes. HDAC2 controlled expression of several prosurvival receptor tyrosine kinases connected to mesenchymal PDAC, including PDGFRα, PDGFRβ, and EGFR. The HDAC2-maintained program disabled the tumor-suppressive arm of the TGFβ pathway, explaining impaired metastasis formation of HDAC2-deficient PDAC. These data identify HDAC2 as a tractable player in the PDAC metastatic cascade. The complexity of the function of epigenetic regulators like HDAC2 implicates that an increased understanding of these proteins is needed for implementation of effective epigenetic therapies. SIGNIFICANCE: HDAC2 has a context-specific role in undifferentiated PDAC and the capacity to disseminate systemically, implicating HDAC2 as targetable protein to prevent metastasis. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34903606     DOI: 10.1158/0008-5472.CAN-20-3209

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Cloning Strategy for HDAC1/HDAC2 Hybrid Protein Expression in Mammalian Cells.

Authors:  Désirée Gül; Sandra Olf; Jan Hagemann; Roland H Stauber; Oliver H Krämer
Journal:  Methods Mol Biol       Date:  2023

Review 2.  Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases.

Authors:  Wynne Sim; Wei-Meng Lim; Ling-Wei Hii; Chee-Onn Leong; Chun-Wai Mai
Journal:  World J Gastroenterol       Date:  2022-05-14       Impact factor: 5.374

Review 3.  Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma.

Authors:  Marcus T T Roalsø; Øyvind H Hald; Marina Alexeeva; Kjetil Søreide
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

Review 4.  Chromatin Dynamics in Digestive System Cancer: Commander and Regulator.

Authors:  Zeru Li; Bangbo Zhao; Cheng Qin; Yuanyang Wang; Tianhao Li; Weibin Wang
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.